Research programme: TGF-beta inhibiting protein gene therapy - Zenith Epigenetics Corp

Drug Profile

Research programme: TGF-beta inhibiting protein gene therapy - Zenith Epigenetics Corp

Alternative Names: TGF-β Shield™

Latest Information Update: 14 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Resverlogix Corporation
  • Class Gene therapies
  • Mechanism of Action Gene transference; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Jun 2013 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 03 Jun 2013 Resverlogix transfers ownership of this research programme to Zenith Epigenetics Corp
  • 13 May 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top